LCD 110 Tablet contains a combination of Levodopa 100 mg and Carbidopa 10 mg, indicated primarily for the management of Parkinson’s disease and Parkinsonian syndromes. Levodopa serves as a precursor to dopamine, effectively replenishing diminished dopamine levels in the brain, thereby alleviating motor symptoms such as bradykinesia, rigidity, and tremors. Carbidopa, a peripheral dopa-decarboxylase inhibitor, enhances the central availability of Levodopa by preventing its peripheral conversion to dopamine, which also reduces peripheral side effects like nausea and cardiovascular disturbances. LCD 110 Tablet is administered orally, with dosage tailored individually based on clinical response and tolerability. It is essential to initiate therapy at the lowest effective dose and adjust gradually to minimize adverse effects, including dyskinesias, orthostatic hypotension, and neuropsychiatric symptoms. The combination is contraindicated in patients with hypersensitivity to either component, narrow-angle glaucoma, or those receiving non-selective monoamine oxidase inhibitors. Caution is advised in patients with cardiovascular, hepatic, or renal impairment. Regular monitoring of therapeutic response and adverse effects is recommended during treatment. LCD 110 Tablet should be used under strict medical supervision, with adherence to prescribed dosing schedules to optimize clinical outcomes in Parkinson’s disease management.